Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by 89bio, Inc.

< Previous 1 2 Next >
89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio to Participate in Upcoming Investor Conferences
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Appoints Francis Sarena as Chief Operating Officer
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Reports Second Quarter 2024 Financial Results and Corporate Updates
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Appoints Charles McWherter, Ph.D., to its Board of Directors
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio to Participate in the BofA Securities 2024 Health Care Conference
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio to Participate in the Leerink Partners Global Biopharma Conference
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio to Participate in the 6th Annual Evercore ISI HEALTHCONx Conference
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.